Understanding the basis of transcutaneous vaccine delivery

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Shenefelt PD. Herbal treatment for dermatologic disorders. Arch. Dermatol. 138(2), 232–242 (2002).
  MedlineGoogle Scholar
• 2 Streilein JW. Skin-associated lymphoid tissues (SALT): origins and functions. J. Invest. Dermatol. 80(Suppl), 12s–16s (1983). •• Seminal work on understanding the role of the skin-associated lymphoid tissue.
  MedlineGoogle Scholar
• 3 Global Commission for the Certification of Smallpox Eradication & World Health Organization. The global eradication of smallpox: final report of the Global Commission for the Certification of Smallpox Eradication, Geneva, December 1979 (1980). http://apps.who.int/iris/handle/10665/68258.
  Google Scholar
• 4 Baxter AL, Cohen LL, Burton M, Mohammed A, Lawson ML. The number of injected same-day preschool vaccines relates to preadolescent needle fear and HPV uptake. Vaccine 35(33), 4213–4219 (2017).
  MedlineGoogle Scholar
• 5 Guo X, Zhong J-Y, Li J-W. Hepatitis C virus infection and vaccine development. J. Clin. Exp. Hepatol. 8(2), 195–204 (2018).
  MedlineGoogle Scholar
• 6 Tomljenovic L, Shaw CA. Aluminum vaccine adjuvants: are they safe? Curr. Med. Chem. 18(17), 2630–2637 (2011).
  Medline CASGoogle Scholar
• 7 van der Laan JW, Gould S, Tanir JY. Safety of vaccine adjuvants: focus on autoimmunity. Vaccine 33(13), 1507–1514 (2015).
  Medline CASGoogle Scholar
• 8 Jung EC, Maibach HI. Animal models for percutaneous absorption. J. Appl. Toxicol. 35(1), 1–10 (2015).
  Medline CASGoogle Scholar
• 9 Lavker RM, Sun TT. Heterogeneity in epidermal basal keratinocytes: morphological and functional correlations. Science 215(4537), 1239–1241 (1982).
  Medline CASGoogle Scholar
• 10 Menon GK. New insights into skin structure: scratching the surface. Adv. Drug Deliv. Rev. 54(Suppl.), S3–S7 (2002).
  Medline CASGoogle Scholar
• 11 Nemes Z, Steinert PM. Bricks and mortar of the epidermal barrier. Exp. Mol. Med. 31(1), 5–19 (1999).
  Medline CASGoogle Scholar
• 12 Kalinin AE, Kajava AV, Steinert PM. Epithelial barrier function: assembly and structural features of the cornified cell envelope. Bioessays 24(9), 789–800 (2002).
  Medline CASGoogle Scholar
• 13 Pasparakis M, Haase I, Nestle FO. Mechanisms regulating skin immunity and inflammation. Nat. Rev. Immunol. 14(5), 289–301 (2014).
  Medline CASGoogle Scholar
• 14 Tong PL, Roediger B, Kolesnikoff N et al. The skin immune atlas: three-dimensional analysis of cutaneous leukocyte subsets by multiphoton microscopy. J. Invest. Dermatol. 135(1), 84–93 (2015).
  MedlineGoogle Scholar
• 15 Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26(26), 3197–3208 (2008).
  Medline CASGoogle Scholar
• 16 Gniadecka M, Jamec G. Quantitative evaluation of chronological aging and photoaging in vivo: studies on skin echogenicity and thickness. Br. J. Dermatol. 139, 815–821 (1998).
  Medline CASGoogle Scholar
• 17 Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Ski. Res. Technol. 11(4), 221–235 (2005).
  MedlineGoogle Scholar
• 18 Shuster S, Black MM, McVitie E. The influence of age and sex on skin thickness, skin collagen and density. Br. J. Dermatol. 93(6), 639–643 (1975).
  Medline CASGoogle Scholar
• 19 Sandby-Møller J, Poulsen T, Wulf HC. Epidermal thickness at different body sites: relationship to age, gender, pigmentation, blood content, skin type and smoking habits. Acta Derm. Venereol. 83(6), 410–413 (2003).
  MedlineGoogle Scholar
• 20 Laurent A, Mistretta F, Bottigioli D et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 25(34), 6423–6430 (2007).
  MedlineGoogle Scholar
• 21 Groswasser J, Kahn A, Bouche B et al. Needle length and injection technique for efficient intramuscular vaccine delivery in infants and children evaluated through an ultrasonographic determination of subcutaneous and muscle layer thickness. Pediatrics 100(3 Pt 1), 400–403 (1997).
  Medline CASGoogle Scholar
• 22 Marples M. In: Chapter 1. The Ecology of the Human Skin. Thomas CC (Ed.). Bannerstone House, IL, USA (1965).
  Google Scholar
• 23 Kearney JN, Harnby D, Gowland G, Holland KT. The follicular distribution and abundance of resident bacteria on human skin. J. Gen. Microbiol. 130(4), 797–801 (1984).
  Medline CASGoogle Scholar
• 24 Gallo RL, Hooper LV. Epithelial antimicrobial defence of the skin and intestine. Nat. Rev. Immunol. 12(7), 503–516 (2012).
  Medline CASGoogle Scholar
• 25 Christensen GJM, Scholz CFP, Enghild J et al. Antagonism between Staphylococcus epidermidis and Propionibacterium acnes and its genomic basis. BMC Genomics 17(1), 1–14 (2016).
  MedlineGoogle Scholar
• 26 Nakatsuji T, Chen TH, Narala S et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Sci. Transl. Med. 9(378), eaah4680 (2017).
  MedlineGoogle Scholar
• 27 Chehoud C, Rafail S, Tyldsley AS, Seykora JT, Lambris JD, Grice EA. Complement modulates the cutaneous microbiome and inflammatory milieu. Proc. Natl Acad. Sci. USA 110(37), 15061–15066 (2013).
  Medline CASGoogle Scholar
• 28 Naik S, Bouladoux N, Wilhelm C et al. Compartmentalized control of skin immunity by resident commensals. Science 337(6098), 1115–1119 (2012).
  Medline CASGoogle Scholar
• 29 Naik S, Bouladoux N, Linehan JL et al. Commensal–dendritic-cell interaction specifies a unique protective skin immune signature. Nature 520(7545), 104–108 (2015).
  Medline CASGoogle Scholar
• 30 Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand. J. Immunol. 70(6), 505–515 (2009).
  Medline CASGoogle Scholar
• 31 Salinas I. The mucosal immune system of teleost fish. Biology (Basel). 4, 525–539 (2015).
  Medline CASGoogle Scholar
• 32 Chen YE, Fischbach MA, Belkaid Y. Skin microbiota–host interactions. Nature 553(7689), 427–436 (2018). • Presents an overview on the interaction between skin microbes and the host, and the consequences on health, including the immune response.
  Medline CASGoogle Scholar
• 33 Thaiss CA, Levy M, Itav S, Elinav E. Integration of innate immune signaling. Trends Immunol. 37(2), 84–101 (2016).
  Medline CASGoogle Scholar
• 34 Belyakov IM, Hammond SA, Ahlers JD, Glenn GM, Berzofsky JA. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 113(7), 998–1007 (2004).
  Medline CASGoogle Scholar
• 35 Glenn GM, Kenney RT, Ellingsworth LR, Frech SA, Hammond SA, Zoeteweij JP. Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin. Expert Rev. Vaccines 2(2), 253–267 (2003).
  Medline CASGoogle Scholar
• 36 Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9(10), 679–691 (2009).
  Medline CASGoogle Scholar
• 37 Miller LS, Modlin RL. Human keratinocyte toll-like receptors promote distinct immune responses. J. Invest. Dermatol. 127(2), 262–263 (2007).
  Medline CASGoogle Scholar
• 38 Lebre MC, Van Der Aar AMG, Van Baarsen L et al. Human keratinocytes express functional toll-like receptor 3, 4, 5, and 9. J. Invest. Dermatol. 127(2), 331–341 (2007).
  Medline CASGoogle Scholar
• 39 Black APB, Ardern-Jones MR, Kasprowicz V et al. Human keratinocyte induction of rapid effector function in antigen-specific memory CD4⁺ and CD8⁺ T cells. Eur. J. Immunol. 37(6), 1485–1493 (2007).
  Medline CASGoogle Scholar
• 40 Brodell LA, Ã B, Rosenthal KS. Skin structure and function the body's primary defense against infection. Infect. Dis. Clin. Pract. 16(2), 113–117 (2008).
  Google Scholar
• 41 Kobayashi M, Yoshiki R, Sakabe J, Kabashima K, Nakamura M, Tokura Y. Expression of toll-like receptor 2, NOD2 and dectin-1 and stimulatory effects of their ligands and histamine in normal human keratinocytes. Br. J. Dermatol. 160(2), 297–304 (2009).
  Medline CASGoogle Scholar
• 42 Partidos CD, Beignon AS, Semetey V, Briand JP, Muller S. The bare skin and the nose as non-invasive routes for administering peptide vaccines. Vaccine 19(17–19), 2708–2715 (2001).
  Medline CASGoogle Scholar
• 43 Kubo A, Nagao K, Yokouchi M, Sasaki H, Amagai M. External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers. J. Exp. Med. 206(13), 2937–2946 (2009).
  Medline CASGoogle Scholar
• 44 Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 8(12), 935–947 (2008).
  Medline CASGoogle Scholar
• 45 Malissen B, Tamoutounour S, Henri S. The origins and functions of dendritic cells and macrophages in the skin. Nat. Rev. Immunol. 14(6), 417–428 (2014).
  Medline CASGoogle Scholar
• 46 Kerstan A, Bröcker EB, Trautmann A. Decisive role of tumor necrosis factor-α for spongiosis formation in acute eczematous dermatitis. Arch. Dermatol. Res. 303(9), 651–658 (2011).
  Medline CASGoogle Scholar
• 47 Ebner S, Nguyen VA, Forstner M et al. Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J. Allergy Clin. Immunol. 119(4), 982–990 (2007).
  Medline CASGoogle Scholar
• 48 Gasque P, Jaffar-Bandjee MC. The immunology and inflammatory responses of human melanocytes in infectious diseases. J. Infect. 71(4), 413–421 (2015).
  MedlineGoogle Scholar
• 49 Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31, 563–604 (2013).
  Medline CASGoogle Scholar
• 50 Gorvel L, Korenfeld D, Tung T, Klechevsky E. Dendritic cell-derived IL-32α: a novel inhibitory cytokine of NK cell function. J. Immunol. 199(4), 1290–1300 (2017).
  Medline CASGoogle Scholar
• 51 Lalor SJ, McLoughlin RM. Memory γδ T Cells – newly appreciated protagonists in infection and immunity. Trends Immunol. 37(10), 690–702 (2016).
  Medline CASGoogle Scholar
• 52 Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3(1), 23–25 (2003).
  Medline CASGoogle Scholar
• 53 Sica AM. Macrophage plasticity and polarization. J. Clin. Invest. 122(3), 787–795 (2012).
  Medline CASGoogle Scholar
• 54 Heib V, Becker M, Taube C, Stassen M. Advances in the understanding of mast cell function. Br. J. Haematol. 142(5), 683–694 (2008).
  Medline CASGoogle Scholar
• 55 Grimbaldeston MA, Nakae S, Kalesnikoff J, Tsai M, Galli SJ. Mast cell-derived IL-10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B. Nat. Immunol. 8(10), 1095–104 (2007).
  Medline CASGoogle Scholar
• 56 Clark RA. Skin-resident T cells: the ups and downs of on site immunity. J. Invest. Dermatol. 130(2), 362–370 (2010).
  Medline CASGoogle Scholar
• 57 Holtmeier W, Kabelitz D. gammadelta T cells link innate and adaptive immune responses. Chem. Immunol. Allergy 86, 151–183 (2005).
  Medline CASGoogle Scholar
• 58 O'Brien RL, Born WK. Dermal γδ T cells - what have we learned? Cell. Immunol. 296(1), 62–69 (2015).
  MedlineGoogle Scholar
• 59 Mehling A, Loser K, Varga G et al. Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J. Exp. Med. 194(5), 615–628 (2001).
  Medline CASGoogle Scholar
• 60 Chen D, Maa YF, Haynes JR. Needle-free epidermal powder immunization. Expert Rev. Vaccin. 1(3), 265–276 (2002).
  Medline CASGoogle Scholar
• 61 Logomasini MA, Stout RR. Jet injection devices for the needle-free administration of compounds, vaccines, and other agents. Int. J. Pharm. Compd. 17(4), 270–280 (2013).
  MedlineGoogle Scholar
• 62 Chen X, Kositratna G, Zhou C, Manstein D, Wu MX. Micro-fractional epidermal powder delivery for improved skin vaccination. J. Control. Rel. 192, 310–316 (2014).
  Medline CASGoogle Scholar
• 63 Baxter J, Mitragotri S. Needle-free liquid jet injections: mechanisms and applications. Expert Rev. Med. Devices 3(5), 565–574 (2006).
  MedlineGoogle Scholar
• 64 Frerichs DM, Ellingsworth LR, Frech SA et al. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine 26(22), 2782–2787 (2008).
  Medline CASGoogle Scholar
• 65 Seid RC, Look JL, Ruiz C et al. Transcutaneous immunization with Intercell's vaccine delivery system. Vaccine 30(29), 4349–4354 (2012).
  Medline CASGoogle Scholar
• 66 Glenn GM, Villar CP, Flyer DC et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect. Immun. 75(5), 2163–2170 (2007).
  Medline CASGoogle Scholar
• 67 Gill HS, Andrews SN, Sakthivel SK et al. Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur. J. Pharm. Sci. 38(2), 95–103 (2009).
  Medline CASGoogle Scholar
• 68 Apitz I, Vogel A. Material ejection in nanosecond Er:YAG laser ablation of water, liver, and skin. Appl. Phys. A Mater. Sci. Process. 81(2), 329–338 (2005).
  CASGoogle Scholar
• 69 Bramson J, Dayball K, Evelegh C, Wan YH, Page D, Smith A. Enabling topical immunization via microporation: a novel method for pain-free and needle-free delivery of adenovirus-based vaccines. Gene Ther. 10(3), 251–260 (2003).
  Medline CASGoogle Scholar
• 70 Arora A, Prausnitz MR, Mitragotri S. Micro-scale devices for transdermal drug delivery. Int. J. Pharm. 364(2), 227–236 (2008).
  Medline CASGoogle Scholar
• 71 Tezel A, Paliwal S, Shen Z, Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 23(29), 3800–3807 (2005).
  Medline CASGoogle Scholar
• 72 Dahlan A, Alpar HO, Stickings P, Sesardic D, Murdan S. Transcutaneous immunisation assisted by low-frequency ultrasound. Int. J. Pharm. 368(1–2), 123–128 (2009).
  Medline CASGoogle Scholar
• 73 Foldvari M, Babiuk S, Badea I. DNA delivery for vaccination and therapeutics through the skin. Curr. Drug Deliv. 3(1), 17–28 (2006).
  Medline CASGoogle Scholar
• 74 Broderick KE, Khan AS, Sardesai NY. DNA vaccination in skin enhanced by electroporation. Methods Mol. Biol. 1143, 123–130 (2014).
  Medline CASGoogle Scholar
• 75 Todorova B, Adam L, Culina S et al. Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques. Sci. Rep. 7(1), 4122 (2017).
  MedlineGoogle Scholar
• 76 Storni T, Kündig TM, Senti G, Johansen P. Immunity in response to particulate antigen-delivery systems. Adv. Drug Deliv. Rev. 57(3), 333–355 (2005).
  Medline CASGoogle Scholar
• 77 Trovato M, De Berardinis P. Novel antigen delivery systems. World J. Virol. 4(3), 156–168 (2015).
  MedlineGoogle Scholar
• 78 Mishra D, Dubey V, Asthana A, Saraf DK, Jain NK. Elastic liposomes mediated transcutaneous immunization against Hepatitis B. Vaccine 24(22), 4847–4855 (2006).
  Medline CASGoogle Scholar
• 79 Mahor S, Rawat A, Dubey PK et al. Cationic transfersomes based topical genetic vaccine against hepatitis B. Int. J. Pharm. 340(1–2), 13–19 (2007).
  Medline CASGoogle Scholar
• 80 Mishra V, Mahor S, Rawat A et al. Development of novel fusogenic vesosomes for transcutaneous immunization. Vaccine 24(27–28), 5559–5570 (2006).
  Medline CASGoogle Scholar
• 81 Vyas SP, Singh RP, Jain S et al. Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int. J. Pharm. 296(1–2), 80–86 (2005).
  Medline CASGoogle Scholar
• 82 Tamayo I, Gamazo C, de Souza Rebouças J, Irache JM. Topical immunization using a nanoemulsion containing bacterial membrane antigens. J. Drug Deliv. Sci. Technol. 42, 207–214 (2017).
  CASGoogle Scholar
• 83 Karande P, Mitragotri S. Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies. Annu. Rev. Chem. Biomol. Eng. 1, 175–201 (2010).
  Medline CASGoogle Scholar
• 84 Cevc G. Transferosomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 13(3–4), 257–388 (1996).
  Medline CASGoogle Scholar
• 85 Chen J, Lu W-L, Gu W, Lu S-S, Chen Z-P, Cai B-C. Skin permeation behavior of elastic liposomes: role of formulation ingredients. Expert Opin. Drug Deliv. 10(6), 845–856 (2013).
  Medline CASGoogle Scholar
• 86 Benson HAE. Elastic liposomes for topical and transdermal drug delivery. Methods Mol. Biol. 605, 77–86 (2010).
  Medline CASGoogle Scholar
• 87 Duangjit S, Opanasopit P, Rojanarata T, Ngawhirunpat T. Effect of edge activator on characteristic and in vitro skin permeation of meloxicam loaded in elastic liposomes. Adv. Mater. Res. Vols. 194–196, 537–540 (2011).
  CASGoogle Scholar
• 88 Garg V, Singh H, Bimbrawh S et al. Ethosomes and transfersomes: principles, perspectives and practices. Curr. Drug Deliv. 14(5), 613–633 (2016).
  Google Scholar
• 89 Prausnitz MR. Microneedles for transdermal drug delivery. Adv. Drug Deliv. Rev. 56(5), 581–587 (2004).
  Medline CASGoogle Scholar
• 90 Donnelly RF, Singh TRR, Morrow DIJ, Woolfson AD. Microneedle-Mediated Transdermal and Intradermal Drug Delivery. Hoboken, Wiley–Blackwell, Oxford, UK (2012).
  Google Scholar
• 91 Larrañeta E, Lutton REM, Woolfson AD, Donnelly RF. Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development. Mater. Sci. Eng. R Reports. 104, 1–32 (2016). •• Identifies the relevance of microneedles as delivery systems. Contains key perspectives for manufacture and commercial development.
  Google Scholar
• 92 Lutton REM, Moore J, Larrañeta E, Ligett S, Woolfson AD, Donnelly RF. Microneedle characterisation: the need for universal acceptance criteria and GMP specifications when moving towards commercialisation. Drug Deliv. Transl. Res. 5(4), 313–331 (2015). • Contains an interesting discussion on commercial development of microneedles.
  MedlineGoogle Scholar
• 93 Tuan-Mahmood TM, McCrudden MTC, Torrisi BM et al. Microneedles for intradermal and transdermal drug delivery. Eur. J. Pharm. Sci. 50(5), 623–637 (2013).
  Medline CASGoogle Scholar
• 94 Indermun S, Luttge R, Choonara YE et al. Current advances in the fabrication of microneedles for transdermal delivery. J. Control. Rel. 185, 130–138 (2014).
  Medline CASGoogle Scholar
• 95 Ripolin A, Quinn J, Larrañeta E, Vicente-Perez EM, Barry J, Donnelly RF. Successful application of large microneedle patches by human volunteers. Int. J. Pharm. 521(1–2), 92–101 (2017).
  Medline CASGoogle Scholar
• 96 Lutton REM, Larrañeta E, Kearney MC, Boyd P, Woolfson AD, Donnelly RF. A novel scalable manufacturing process for the production of hydrogel-forming microneedle arrays. Int. J. Pharm. 494(1), 417–429 (2015).
  Medline CASGoogle Scholar
• 97 Kommareddy S, Baudner BC, Oh S, Kwon SY, Singh M, O'Hagan DT. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J. Pharm. Sci. 101(3), 1021–1027 (2012).
  Medline CASGoogle Scholar
• 98 Raphael AP, Prow TW, Crichton ML, Chen X, Fernando GJP, Kendall MAF. Targeted, needle-free vaccinations in skin using multilayered, densely-packed dissolving microprojection arrays. Small 6(16), 1785–1793 (2010).
  Medline CASGoogle Scholar
• 99 Sullivan SP, Koutsonanos DG, Del Pilar Martin M et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16(8), 915–920 (2010).
  Medline CASGoogle Scholar
• 100 Rouphael NG, Paine M, Mosley R et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, Phase I trial. Lancet 390(10095), 649–658 (2017).
  Medline CASGoogle Scholar
• 101 Matsuo K, Hirobe S, Yokota Y et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. J. Control. Rel. 160(3), 495–501 (2012).
  Medline CASGoogle Scholar
• 102 Matsuo K, Okamoto H, Kawai Y et al. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease. J. Neuroimmunol. 266(1–2), 1–11 (2014).
  Medline CASGoogle Scholar
• 103 Kommareddy S, Baudner BC, Bonificio A et al. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine 31(34), 3435–3441 (2013).
  Medline CASGoogle Scholar
• 104 Zhu Q, Zarnitsyn VG, Ye L et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl Acad. Sci. USA 106(19), 7968–7973 (2009).
  Medline CASGoogle Scholar
• 105 Wang BZ, Gill HS, He C et al. Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. J. Control. Rel. 178, 1–7 (2014).
  Medline CASGoogle Scholar
• 106 Edens C, Collins ML, Ayers J, Rota PA, Prausnitz MR. Measles vaccination using a microneedle patch. Vaccine 31(34), 3403–3409 (2013).
  Medline CASGoogle Scholar
• 107 Vrdoljak A, McGrath MG, Carey JB et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J. Control. Rel. 159(1), 34–42 (2012).
  Medline CASGoogle Scholar
• 108 Kim NW, Lee MS, Kim KR et al. Polyplex-releasing microneedles for enhanced cutaneous delivery of DNA vaccine. J. Control. Rel. 179, 11–17 (2014).
  Medline CASGoogle Scholar
• 109 Donnelly RF, Larrañeta E. Microarray patches: potentially useful delivery systems for long-acting nanosuspensions. Drug Discov. Today 23(5), 1026–1033 (2018). •• Recent review on micropatches. Explore the key considerations in the development of combined drug-delivery systems.
  Medline CASGoogle Scholar
• 110 Demuth PC, Moon JJ, Suh H, Hammond PT, Irvine DJ. Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery. ACS Nano. 6(9), 8041–8051 (2012).
  Medline CASGoogle Scholar
• 111 Burton SA, Ng CY, Simmers R et al. Rapid intradermal delivery of liquid formulations using a hollow microstructured array. Pharm. Res. 28(1), 31–40 (2011).
  Medline CASGoogle Scholar
• 112 Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25(52), 8833–8842 (2007).
  Medline CASGoogle Scholar
• 113 Mikszta JA, Dekker JP, Harvey NG et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun. 74(12), 6806–6810 (2006).
  Medline CASGoogle Scholar
• 114 Laurent PE, Bourhy H, Fantino M, Alchas P, Mikszta JA. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 28(36), 5850–5856 (2010).
  MedlineGoogle Scholar
• 115 Morefield GL, Tammariello RF, Purcell BK et al. An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock. J. Immune Based Ther. Vaccines 6, 5 (2008).
  MedlineGoogle Scholar
• 116 Larrañeta E, McCrudden MTC, Courtenay AJ, Donnelly RF. Microneedles: a new frontier in nanomedicine delivery. Pharm. Res. 33(5), 1055–1073 (2016).
  Medline CASGoogle Scholar
• 117 Zaric M, Lyubomska O, Touzelet O et al. Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D, l-Lactide-Co-Glycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano. 7(3), 2042–2055 (2013).
  Medline CASGoogle Scholar
• 118 Zaric M, Lyubomska O, Poux C et al. Dissolving microneedle delivery of nanoparticle-encapsulated antigen elicits efficient cross-priming and th1 immune responses by murine langerhans cells. J. Invest. Dermatol. 135(2), 425–434 (2015).
  Medline CASGoogle Scholar
• 119 Zhang Y, Ng Weibeng, Feng X, Cao F, Xu Huaxi. Lipid vesicular nanocarrier: quick encapsulation efficiency determination and transcutaneous application. Int. J. Pharm. 516(1–2), 225–230 (2017). • Highlights the immune mechanisms underlying effective immunization by using micronneedles.
  Medline CASGoogle Scholar
• 120 Bussio JI, Molina-Perea C, González-Aramundiz JV. Lower-size chitosan nanocapsules for transcutaneous antigen delivery. Nanomaterials (Basel). 8(9), doi: 10.3390/nano8090659 (2018) (Epub ahead of print).
  MedlineGoogle Scholar
• 121 Bernardi DS, Bitencourt C, da Silveira DS et al. Effective transcutaneous immunization using a combination of iontophoresis and nanoparticles. Nanomedicine 12(8), 2439–2448 (2016). • The authors illustrate the effectiveness of using nanoparticles as antigen-delivery systems through the skin.
  Medline CASGoogle Scholar
• 122 Leone M, Mönkäre J, Bouwstra JA, Kersten G. Dissolving microneedle patches for dermal vaccination. Pharm. Res. 34(11), 2223–2240 (2017).
  Medline CASGoogle Scholar
• 123 Warrell MJ. Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure. Travel Med. Infect. Dis. 10(1), 1–15 (2012).
  Medline CASGoogle Scholar
• 124 Millar JD, Roberto RR, Wulff H, Wenner HA, Henderson DA. Smallpox vaccination by intradermal jet injection. I. Introduction, background and results of pilot studies. Bull. World Health Organ. 41(6), 749–760 (1969).
  Medline CASGoogle Scholar
• 125 Mohammed AJ, AlAwaidy S, Bawikar S et al. Fractional doses of inactivated poliovirus vaccine in Oman. N. Engl. J. Med. 362(25), 2351–2359 (2010).
  Medline CASGoogle Scholar
• 126 Resik S, Tejeda A, Lago PM et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J. Infect. Dis. 201(9), 1344–1352 (2010).
  MedlineGoogle Scholar
• 127 Resik S, Tejeda A, Mach O et al. Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: association between injection quality and immunogenicity. Vaccine 33(43), 5873–5877 (2015).
  MedlineGoogle Scholar
• 128 Dean HJ, Chen D. Epidermal powder immunization against influenza. Vaccine 23(5), 681–686 (2004).
  Medline CASGoogle Scholar
• 129 Jones S, Evans K, McElwaine-Johnn H et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled Phase Ib clinical trial. Vaccine 27(18), 2506–2512 (2009).
  Medline CASGoogle Scholar
• 130 Frech SA, DuPont HL, Bourgeois AL et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a Phase II, randomised, double-blind, placebo-controlled field trial. Lancet 371(9629), 2019–2025 (2008).
  Medline CASGoogle Scholar
• 131 Behrens RH, Cramer JP, Jelinek T et al. Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a Phase III, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect. Dis. 14(3), 197–204 (2014).
  Medline CASGoogle Scholar
• 132 Kwon KM, Lim S-M, Choi S et al. Microneedles: quick and easy delivery methods of vaccines. Clin. Exp. Vaccine Res. 6(2), 156–159 (2017).
  Medline CASGoogle Scholar
• 133 Leroux-Roels I, Weber F. Intanza^® 9 μg intradermal seasonal influenza vaccine for adults 18 to 59 years of age. Hum. Vaccin. Immunother. 9(1), 115–121 (2013).
  Medline CASGoogle Scholar
• 134 Arnou R, Icardi G, De Decker M et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter Phase III study. Vaccine 27(52), 7304–7312 (2009).
  Medline CASGoogle Scholar
• 135 Troy SB, Kouiavskaia D, Siik J et al. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV-infected adults. J. Infect. Dis. 211(12), 1969–1976 (2015).
  Medline CASGoogle Scholar
• 136 Anand A, Zaman K, Estívariz CF et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine 33(48), 6816–6822 (2015).
  Medline CASGoogle Scholar
• 137 Vescovo P, Rettby N, Ramaniraka N et al. Safety, tolerability and efficacy of intradermal rabies immunization with DebioJect^™. Vaccine 35(14), 1782–1788 (2017).
  Medline CASGoogle Scholar
• 138 Laurent PE, Bourhy H, Fantino M, Alchas P, Mikszta JA. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 28(36), 5850–5856 (2010).
  MedlineGoogle Scholar
• 139 Rouphael NG, Paine M, Mosley R et al. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, Phase I trial. Lancet 390(10095), 649–658 (2017).
  Medline CASGoogle Scholar
• 140 Hirobe S, Azukizawa H, Hanafusa T et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials 57, 50–58 (2015).
  Medline CASGoogle Scholar
• 141 Marshall S, Sahm LJ, Moore AC. The success of microneedle-mediated vaccine delivery into skin. Hum. Vaccin. Immunother. 12(11), 2975–2983 (2016). •• Compares primary scientific literature pertaining to micronneedle-mediated in vivo vaccination programs.
  MedlineGoogle Scholar
• 142 Haidari G, Cope A, Miller A et al. Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial. Sci. Rep. 7(1), 1–11 (2017).
  Medline CASGoogle Scholar
• 143 Kim H, Theogarajan LS, Pennathur S. A repeatable and scalable fabrication method for sharp, hollow silicon microneedles. J. Micromech. Microeng. 28, 035007 (2018).
  Google Scholar
• 144 McCrudden MTC, Alkilani AZ, Courtenay AJ et al. Considerations in the sterile manufacture of polymeric microneedle arrays. Drug Deliv. Transl. Res. 5(1), 3–14 (2014).
  Google Scholar
• 145 Donnelly RF, Singh TRR, Tunney MM et al. Microneedle arrays allow lower microbial penetration than hypodermic needles in vitro. Pharm. Res. 26(11), 2513–2522 (2009).
  Medline CASGoogle Scholar
• 146 Donnelly RF, Majithiya R, Singh TRR et al. Design, optimization and characterisation of polymeric microneedle arrays prepared by a novel laser-based micromoulding techniques. Pharm. Res. 28, 41–57 (2010).
  MedlineGoogle Scholar